Anavex grants director Donhauser 50,000 stock options

Q: How many stock options did the AVXL director receive?

Peter D.O. Donhauser received 50,000 stock options on November 3, 2026. The options are for common stock and have an exercise price of $1.20 per share.

The options vest in three substantially equal annual installments beginning March 31, 2027, with an exercise price of $1.20 per share.

Available on EDGAR 11/06/2026 - 08:14 PM EST Accepted by SEC EDGAR 11/06/2026 - 08:14 PM EST

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Peter D.O. Donhauser, a director of ANAVEX LIFE SCIENCES CORP. (AVXL), acquired a grant of 50,000 stock options for common stock on November 3, 2026. The options have an exercise price of $1.20 per share and expire November 2, 2036. They vest in three substantially equal annual installments beginning March 31, 2027.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider Donhauser Peter D.O.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) ^F1	50,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 50,000 options (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 50,000 options (Direct)

Footnotes (1)

F1. The option vests in three substantially equal annual installments beginning on March 31, 2027

Key Figures

Stock options granted: 50,000 options Exercise price: $1.20 per share First vesting date: March 31, 2027 +1 more

4 metrics

Stock options granted 50,000 options Granted November 3, 2026

Exercise price $1.20 per share Stock options for common stock

First vesting date March 31, 2027 Beginning of three substantially equal annual installments

Expiration date November 2, 2036 Stock options

Key Terms

Stock Option (Right to Buy), exercise price, vests in three substantially equal annual installments

3 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

exercise price financial

"exercise price of $1.20"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vests in three substantially equal annual installments financial

"The option vests in three substantially equal annual installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many stock options did the AVXL director receive?

Peter D.O. Donhauser received 50,000 stock options on November 3, 2026. The options are for common stock and have an exercise price of $1.20 per share.

When do Peter D.O. Donhauser's AVXL options vest?

The options vest in three substantially equal annual installments beginning March 31, 2027. They expire November 2, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donhauser Peter D.O.

(Last)

(First)

(Middle)

630 5TH AVENUE 20TH FLOOR

(Street)

NEW YORK

10111

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANAVEX LIFE SCIENCES CORP. [ AVXL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.2	11/03/2026		A		50,000		⁽¹⁾	11/02/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. The option vests in three substantially equal annual installments beginning on March 31, 2027

	/s/Peter Donhauser	11/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR